Tempus is a technology company that is building the world's largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/26/17 | $70,000,000 | Series C |
Revolution Growth | undisclosed |
| 09/01/18 | $110,000,000 | Series E |
Baillie Gifford New Enterprise Associates Revolution Growth T. Rowe Price | $2,000,000,000 |
